Metabolism of glucagon by dipeptidyl peptidase IV (CD26)

Regulatory Peptides

Volumn 96, Issue 3, 2001, Pages 133-141

  Pospisilik, John A ^c   Hinke, Simon A ^c   Pederson, Raymond A ^c   Hoffmann, Torsten ^a   Rosche, Fred ^a   Schlenzig, Dagmar ^a   Glund, Konrad ^a   Heiser, Ulrich ^a   McIntosh, Christopher H S ^c   Demuth, Hans Ulrich ^a,b  

^a PROBIODRUG AG   (Germany)

^b Hans Knoell Inst Nat Prod Res J   (Germany)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

GIP; GLP 1; Glucose; Incretins; MALDI TOF mass spectrometry; Peptide inactivation; Rodent

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON;

ANIMAL EXPERIMENT; ARTICLE; BIOASSAY; CAPILLARY ZONE ELECTROPHORESIS; CONTROLLED STUDY; CYCLIZATION; DIABETES MELLITUS; DRUG ACTIVITY; DRUG DEGRADATION; DRUG INACTIVATION; DRUG METABOLISM; MALE; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; RAT;

RODENTIA; SUIDAE;

EID: 0035847312     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(00)00170-1     Document Type: Article

References (49)

1. Glucose counter-regulatory hormones: physiology, pathophysiology, and relevance to clinical hypoglycemia
2. Gastric inhibitory polypeptide
3. The incretin concept and its relevance to diabetes
4. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV
5. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum
6. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo
7. Investigation of GIP1-42 and GLP-1 7-36 degradation in vitro by dipeptidyl peptidase IV (DPIV) using matrix-assisted laser desorption/ionization-time of flight mass spectometry (MALDI-TOF MS): a novel kinetic approach
8. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide
9. The enteroinsular axis in dipeptidyl peptidase IV-negative rats
10. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptides 1 in the anesthetized pig
11. 2-terminus in type II diabetic patients and in healthy subjects
12. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-Thiazolidide
13. Hepatic metabolism of glucagon in the dog: contribution of the liver to overall metabolic disposal of glucagon
14. Glucagon metabolism in man. Studies on the metabolic clearance rate and the plasma acute disappearance time of glucagon in normal and diabetic subjects
15. Inactivation and degradation of glucagon by dipeptidyl aminopeptidase I (cathepsin C) of rat liver
16. Polypeptide degradation by dipeptidyl aminopeptidase I (cathepsin C) and related peptidases
17. Human dipeptidyl peptidase I. Gene characterization, localization and expression
18. Degradation of glucagons
19. Kinetic studies on hepatic handling of glucagon using the model of non recirculating perfused rat livers
20. The renal handling of glucagon
21. Transport and hydrolysis of glucagon in the proximal nephron
22. Glucagon degradation by luminal and basolateral rabbit tubular membranes
23. Role of dipeptidyl petidase IV in uptake of peptide nitrogen from β-casomorphin in rabbit renal BBMV
24. Proline-dependent structural and biological properties of peptides and proteins
25. Catalytic mechanism of dipeptidyl peptidase
26. Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs
27. Dipeptidyl peptidase IV. (DPP-IV) from pig kidney cleaves analogs of bovine growth hormone-releasing factor (bGRF) modified at position 2 with Ser, Thr, or Val. Extended DPP-IV substrate specificity?
28. Structure-function relationships in glucagon: properties of highly purified des-As-1-monoiodo and (des-Asn-28-Thr-29) homoserine lactone-27 glucagon
29. Conformational considerations in the design of glucagon agonists and antagonists: Examination using synthesis analogues
30. Dipeptidyl peptidase IV degradation of glucagon: characterization of glucagon degradation products and DPIV resistant analogs
31. Kinetische Untersuchungen an der Dipeptidyl-Peptidase IV [Kinetics of dipeptidyl-peptidase IV]
32. Proteolytic Processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV
33. Regulated expression, processing, and secretion of dog mast cell dipeptidyl peptidase I
34. Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction
35. Transglutaminases: Protein cross-linking enzymes in tissues and body fluids
36. Identification of a mammalian glutaminyl cyclase converting glutaminyl into pyroglutamyl peptides
37. Dipeptidyl Peptidase IV (CD26)-role in the inactivation of regulatory peptides
38. The degradation of bioactive peptides and proteins by dipeptidyl peptidase IV from human placenta
39. Specific localization of membrane dipeptidase and dipeptidyl peptidase IV in secretion granules of two different pancreatic islet cells
40. Glucagon and other proglucagon-derived peptides
41. Stability of endogenous immunoreactive glucagon (IRG) in animal blood
42. Glucagon: structure-function relationships investigated by sequence deletions
43. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor
44. A synthetic glucagon-like peptide-1 analog with improved plasma stability
45. Biological activity of GLP-1 analogues with N-terminal modifications
46. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity
47. Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1
48. 2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity